We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Genzyme and Isis strike megadeal.
- Authors
Mack, George S.
- Abstract
The article reports on the signing of a $1.9 billion agreement between Genzyme and Isis Pharmaceuticals in the U.S. According to the author, the agreement is to in-license the cholesterol-lowering antisense drug mipomersen. He added that Genzyme will pay $325 million up front for the powerful drug mipomersen, an antisense treatment that slashes cholesterol levels. Moreover, mipomersen is a second-generation antisense phosphorothioate oligonucleotide inhibitor that is thought to act by binding mRNA encoding apolipoprotein B-100.
- Subjects
UNITED States; BIOTECHNOLOGY; MERGERS &; acquisitions; ISOPENTENOIDS; MESSENGER RNA; CHOLESTEROL; APOLIPOPROTEIN B; GENZYME Corp.; IONIS Pharmaceuticals Inc.
- Publication
Nature Biotechnology, 2008, Vol 26, Issue 3, p251
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0308-251